Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5923148 | 0.93 | HTT (0.48) | VSIRADORA3KMT2APOLBMEN1 | |
| SCHEMBL5923131 | 0.89 | MAPT (0.46) | VSIRKMT2AMEN1MAPTTP53 | |
| SCHEMBL5923099 | 0.85 | MITF (0.47) | VSIRKMT2APOLBMEN1MAPT | |
| SCHEMBL5923340 | 0.84 | MAPT (0.44) | VSIRKMT2APOLBMAPTTP53 | |
| SCHEMBL5923163 | 0.82 | RAB9A (0.52) | ADORA3KMT2APOLBMEN1MAPT | |
| SCHEMBL5923240 | 0.82 | SMN1; SMN2 (0.50) | VSIRKMT2AMEN1MAPTTP53 | |
| SCHEMBL5923172 | 0.80 | MAPK1 (0.50) | KMT2AMEN1 | |
| SCHEMBL4979855 | 0.80 | MGLL (0.66) | ADORA3POLBMGLLCNR1 | |
| SCHEMBL5923231 | 0.79 | SMN1; SMN2 (0.50) | KMT2APOLBMEN1MAPTTP53 | |
| SCHEMBL5923153 | 0.78 | HTT (0.46) | KMT2APOLBMEN1MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | claimed |
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | PIGS, GUCY1A1, GUCY1B1 | VSIR 2810/4885ADORA3 164/4885KMT2A 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.